S- Editor Liu Y L- Editor Anand BS E- Editor Li HY
Published online Dec 7, 2007. doi: 10.3748/wjg.v13.i45.6003
Revised: September 3, 2007
Accepted: October 25, 2007
Published online: December 7, 2007
AIM: To investigate an association between N-acetyltransferase 2 (NAT2)-haplotypes/diplotypes and adverse effects in Japanese pulmonary tuberculosis patients.
METHODS: We studied 100 patients with pulmonary TB treated with anti-TB drugs including INH. The frequencies and distributions of single nucleotide polymorphisms, haplotypes, and diplotypes of NAT2 were determined by the PCR-restriction fragment length polymorphism method, and the results were compared between TB patients with and without adverse effect, using multivariate logistic regression analysis.
RESULTS: Statistical analysis revealed that the frequency of a variant haplotype, NAT2*6A, was significantly increased in TB patients with hepatotoxicity, compared with those without hepatotoxicity [P = 0.001, odds ratio (OR) = 3.535]. By contrast, the frequency of a wild-type (major) haplotype, "NAT2*4", was significantly lower in TB patients with hepatotoxicity than those without hepatotoxicity (P < 0.001, OR = 0.265). There was no association between NAT2-haplotypes and skin rash or eosinophilia.
CONCLUSION: The present study shows that NAT2 is one of the determinants of anti-TB drug-induced hepatotoxicity. Moreover, the haplotypes, NAT2*4 and NAT2*6A, are useful new biomarkers for predicting anti-TB drug-induced hepatotoxicity.
Citation: Higuchi N, Tahara N, Yanagihara K, Fukushima K, Suyama N, Inoue Y, Miyazaki Y, Kobayashi T, Yoshiura KI, Niikawa N, Wen CY, Isomoto H, Shikuwa S, Omagari K, Mizuta Y, Kohno S, Tsukamoto K.
NAT2*6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol 2007; 13(45): 6003-6008
- URL: https://www.wjgnet.com/1007-9327/full/v13/i45/6003.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i45.6003
Tuberculosis (TB) is a re-emerging infectious disease that was declared a global health problem by the World Health Organization in 1993. Since there were 9 million new TB cases and approximately 2 million TB deaths in 2004, and more than 80% of all TB patients live in sub-Saharan Africa and Asia, the epidemiology and control of TB remain important public health issues[1,2]. However, the management of TB is associated with serious problems, including disease relapse in elderly patients, occurrence in acquired immunodeficiency syndrome, development of adverse effects of anti-TB drugs, and increase in the prevalence of multidrug-resistant Mycobacterium tuberculosis[2-5]. In particular, poor compliance or non-compliance with anti-TB drugs because of adverse effects, such as hepatotoxicity, skin rash, drug fever, peripheral neuritis, eosinophilia, and/or hyperuricemia, may lead to decrease in the quality-of-life of TB patients and appearance of multidrug-resistant M. tuberculosis. An important focus of previous studies was drug-induced hepatotoxicity, because it constitutes a major and severe adverse effect in the treatment of tuberculosis. Although the common risk factors for hepatotoxicity include advanced age[6,7], gender[7-10], malnutrition[6,9], complications of diseases[8,10,11], and alcohol intake[6,8,12], genetic factors also have an important impact on the likelihood of the development of drug-induced hepatotoxicity. Case-control studies with candidate genes in the affected populations have identified several possible susceptibility genes, e.g., N-acetyltransferase 2 (NAT2)[13-17], cytochrome P450 2E1 (CYP2E1)[16,18], glutathione S-transferase M1 (GSTM1)[16,19], glutathione S-transferase T1 (GSTT1)[16,19], and HLA-DQA1/-DQB1.
We focused our research on NAT2 as a candidate gene associated with drug-induced hepatotoxicity because NAT2 is the main enzyme involved in isoniazid (INH) metabolism, and is expressed in the liver. Diminution or disturbance of NAT2 activity could result in the accumulation of precursors, such as hydrazine and acetylhydrazine in the liver, leading to hepatotoxicity[21-23]. Furthermore, the degree of metabolism with regard to NAT2 varies among individuals, suggesting that genetic variations contribute to the metabolic activation capacity. Although studies on the association between NAT2 phenotype (slow acetylator) and anti-TB drug-induced hepatotoxicity have been reported from Taiwan[15,18], India[6,16], and Japan[13,14,17], no study has examined the association between hepatotoxicity and haplotypes/diplotypes that are composed of single nucleotide polymorphisms (SNPs). In the present study, we report our findings of the association between NAT2 haplotypes/diplotypes and anti-TB drug-induced adverse effects, especially hepatotoxicity, in Japanese TB patients.
The study subjects comprised of 100 patients with new onset of pulmonary TB treated with a INH- (400 mg/d) and rifampicin (RFP, 450 mg/d)-containing regimen for six or nine months, between the years of 2003 and 2005 (Table 1). All subjects were Japanese who were recruited randomly from four general health clinics in the Nagasaki area of Japan. The study protocol was approved by the Committee for the Ethical Issue on Human Genome and Gene Analysis in Nagasaki University, and written informed consent was obtained from each patient.
|Number of patients||100|
|Age range (yr)||22-94|
|Age (mean ± SD)||64.0 ± 17.4|
|Body mass index (kg/m2)||20.3 ± 2.9|
The diagnosis of pulmonary TB was made on the basis of symptoms, chest radiographic infiltrates, and presence of acid-fast bacilli on sputum smear and M. tuberculosis on sputum culture. Patients with liver cirrhosis, chronic and acute hepatitis, alcoholic liver disease, and other chronic liver diseases were excluded from the study.
Patients with TB were classified into the following two subgroups: those with adverse effects such as hepatotoxicity, skin rash, and eosinophilia, and those without any side effects. Drug-induced hepatotoxicity was defined according to the criteria of the International Consensus Meeting, i.e., development of a two-fold or more increase in serum alanine aminotransferase (ALT) level above the upper limit of the normal range: N (≤ 42 IU/L), or a combined increase of over 2 N in serum aspartate aminotransferase (AST, N≤ 33 IU/L) and total bilirubin (TB, N≤ 1.5 mg/dL). The presence of > 450 eosinophils/mL was defined as eosinophilia.
Genomic DNA was extracted from peripheral blood leukocytes of each patient using the DNA Extracter WB-Rapid Kit (Wako, Osaka, Japan), according to the manufacturer’s protocol. SNPs of NAT2 deposited in the SNP-database were determined with PCR-restriction fragment length polymorphism (RFLP) method as described previously[27,28]. PCR was performed in a 25-μL reaction mixture containing 20 ng of genomic DNA, 20 mmol/L Tris-HCl (pH 8.4), 50 mmol/L KCl, 1.5 mmol/L MgCl2, 200 μmol/L dNTP, 0.4 μmol/L each of sense and antisense primers, and 1.5 U Taq DNA polymerase (Invitrogen, Carlsbad, CA, USA) with a DNA thermal cycler, GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA, USA), according to the following protocol: initial denaturation at 95°C for 5 min; 35 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 30 s; and a final extension at 72°C for 5 min. Subsequently, the PCR product was digested by restriction enzyme (TaKaRa Biomedical, Shiga, Japan) for detection of each SNP. A SNP, C282T, was detected by digestion with Fok I. Likewise, C481T, G590A, and G857A were detected by Kpn I, Taq I, or Bam HI, respectively. These fragments were subjected to electrophoresis on a 2% agarose gel, and visualized with UV transilluminator (Alpha Innotech, San Leandro, CA, USA) after ethidium bromide (Invitrogen) staining. Haplotypes were determined to be based on a combination of four SNPs (Table 2)[26,28].
Data obtained are shown as mean ± standard deviation (SD). Clinico-pathological parameters were compared between TB patients with and without adverse effect, using the Mann-Whitney U test, χ2 test with Yates’ correction, and Fisher’s exact test. Expected allele frequencies were calculated from respective single allele frequencies according to the Hardy-Weinberg equilibrium. The observed and expected allele frequencies were compared by a χ2 test using SNP Alyze 6.0 standard (Dynacom Inc., Chiba, Japan). To evaluate odds ratio (OR) with 95% confidence interval (95% CI) for the susceptibility to anti-TB drug-induced adverse effects, haplotype and diplotype frequencies were compared between TB patients with and without adverse effects, using multivariate logistic regression analysis. A P value of 0.05 or less was considered statistically significant. SPSS 14.0 (SPSS Japan Inc., Tokyo, Japan) program package was used for all statistical analyses.
Out of the 100 TB patients enrolled in the study, 50 (50%) patients had anti-TB drug-induced adverse effects, 18 hepatotoxicity, 25 skin rash, and 34 eosinophilia. There were no differences in the clinical characteristics and baseline laboratory data (before chemotherapy) between TB patients with and without adverse effects (Table 3). However, eosinophilia developed less frequently in female patients than male patients (P = 0.0186). During TB chemotherapy, patients with hepatotoxicity had 8-times higher serum levels of ALT and AST than those without hepatotoxicity (P < 0.0001). Likewise, during therapy, ALT values and eosinophil counts were significantly higher in patients with skin rash compared to those without skin rash (P = 0.0245 and P = 0.0058, respectively). Moreover, eosinophils in patients with eosinophilia were increased in number compared with those without this complication (P < 0.0001).
|(n = 18)||(n = 82)||(n = 25)||(n = 75)||(n = 34)||(n = 66)|
|Age (mean ± SD)||60.8 ± 17.7||64.7 ± 17.3||0.3942||63.6 ± 18.1||64.7 ± 17.3||0.9028||63.3 ± 19.5||64.4 ± 16.3||0.7598|
|Body mass index (kg/m2)||19.6 ± 2.3||20.5 ± 3.1||0.2721||19.8 ± 2.5||20.6 ± 3.1||0.2626||19.8 ± 2.9||20.6 ± 3.0||0.2684|
|ALT (IU/L)||18.0 ± 10.4||21.1 ± 16.6||0.4527||23.1 ± 25.8||19.7 ± 10.4||0.3392||25.9 ± 24.4||17.8 ± 6.8||0.6571|
|AST (IU/L)||29.1 ± 26.8||26.8 ± 23.3||0.7188||31.3 ± 39.2||25.9 ± 15.9||0.3268||35.4 ± 38.5||23.0 ± 7.8||0.4277|
|TB (mg/dL)||0.48 ± 0.19||0.64 ± 0.43||0.1115||0.61 ± 0.44||0.61 ± 0.39||0.9874||0.62 ± 0.44||0.61 ± 0.38||0.9490|
|Creatinine (mg/dL)||0.64 ± 0.13||0.88 ± 1.10||0.3482||0.72 ± 0.28||0.87 ± 1.13||0.5121||0.82 ± 0.47||0.84 ± 1.17||0.9092|
|Eosinophils (/μL)||105.1 ± 120.6||115.5 ± 121.8||0.7434||104.7 ± 93.7||116.6 ± 129.3||0.6750||141.3 ± 133.4||99.3 ± 112.6||0.1011|
|During TB chemotherapy|
|Peak ALT (IU/L)||316.2 ± 281.7||40.0 ± 19.5||< 0.0001||147.8 ± 281.7||61.6 ± 88.1||0.0245||129.6 ± 284.1||59.2 ± 75.4||0.3885|
|Peak AST (IU/L)||294.5 ± 353.6||36.7 ± 21.5||< 0.0001||139.7 ± 222.9||73.1 ± 128.9||0.1325||116.3 ± 175.9||76.0 ± 149.3||0.2107|
|Peak TB (mg/dL)||1.20 ± 1.16||0.74 ± 0.53||0.0101||0.78 ± 0.47||0.84 ± 0.77||0.7039||0.92 ± 0.89||0.77 ± 0.58||0.3241|
|Peak Creatinine (mg/L)||0.76 ± 0.13||0.96 ± 1.23||0.4742||0.81 ± 0.13||0.97 ± 1.28||0.5316||0.87 ± 0.31||0.96 ± 1.36||0.7098|
|Peak Eosinophils (/μL)||692.4 ± 929.1||461.1 ± 844.7||0.4538||668.4 ± 773.9||447.5 ± 885.1||0.0058||1028.1 ± 1327.9||232.1 ± 114.9||< 0.0001|
In the 100 TB patients examined, we identified three haplotypes composed of four SNPs (Table 4). One haplotype, “NAT2*4” is a wild-type (major type), while the other haplotypes are variants (minor types). Distribution of SNPs and haplotypes among patients corresponded well with the Hardy-Weinberg equilibrium, implying that our samples had a homogeneous genetic background, and was consistent with previous observations[13,14,17]. However, since the frequencies of two haplotypes, NAT2*11 and NAT2*13, were very low, they were not used for further statistical analysis.
|Haplotype||Present(%)||Absent(%)||OR||95% CI||P||Present(%)||Absent(%)||OR||95% CI||P||Present(%)||Absent(%)||OR||95% CI||P|
|NAT2*4||16 (44.4)||120 (73.2)||0.265||0.129-0.546||< 0.001||34 (68.0)||102 (68.0)||1.00||0.503-1.987||1.000||45 (66.2)||91 (68.9)||0.880||0.472-1.642||0.688|
|NAT2*6A||14 (38.9)||29 (17.7)||3.535||1.648-7.585||0.001||12 (24.0)||31 (20.7)||1.22||0.570-2.607||0.609||15 (22.0)||28 (21.2)||1.052||0.517-2.138||0.889|
|NAT2*7B||6 (16.7)||15 (9.1)||2.235||0.818-6.104||0.117||4 (8.0)||17 (11.3)||0.70||0.226-2.170||0.537||8 (11.8)||13 (9.9)||1.227||0.482-3.124||0.667|
Multivariate logistic regression analyses revealed that the frequency of a variant haplotype “NAT2*6A”, which is composed of two SNPs (C282T and G590A), was significantly increased in TB patients with hepatotoxicity, compared with those without hepatotoxicity (P = 0.001, OR = 3.535, 95% CI: 1.648-7.585) (Table 4). By contrast, the frequency of the wild-type (major) haplotype, “NAT2*4”, was significantly lower in TB patients with hepatotoxicity than those without hepatotoxicity (P < 0.001, OR = 0.265). There were no significant differences in the frequency of NAT2-haplotypes between TB patients with and without skin rash or eosinophilia (Table 4).
We identified six diplotypes composed of three haplotypes (Table 5). Distributions of the diplotypes in our study population were consistent with previous observations [13,14,17]. Of a total of 18 TB patients with hepatotoxicity, 3 (16.6%) had a diplotype, “NAT2*6A/*7B”; using multivariate logistic regression analyses, the frequency was significantly higher than in patients without hepatotoxicity (2/82, 2.4%; P = 0.029, OR = 8.000, 95% CI: 1.230-52.023) (Table 5). On the other hand, the frequency of another diplotype, “NAT2*4/*4”, was significantly lower in TB patients with hepatotoxicity than those without hepatotoxicity (P = 0.032, OR = 0.272). There was no difference in the frequency of NAT2-diplotypes between TB patients with and without skin rash or eosinophilia (Table 5).
|Diplotype||Present(%)||Absent(%)||OR||95% CI||P||Present(%)||Absent(%)||OR||95% CI||P||Present(%)||Absent(%)||OR||95% CI||P|
|NAT2*4/*4||4 (22.2)||42 (51.2)||0.272||0.083-0.897||0.032||12 (48.0)||34 (45.3)||1.113||0.449-2.757||0.817||14 (41.2)||32 (48.5)||0.744||0.322-1.717||0.488|
|NAT2*4/*6A||7 (38.9)||23 (28.1)||1.632||0.564-4.726||0.366||7 (28.0)||23 (30.7)||0.879||0.323-2.394||0.801||11 (32.4)||19 (28.9)||1.183||0.484-2.894||0.713|
|NAT2*4/*7B||1 (5.6)||13 (15.9)||0.312||0.038-2.555||0.278||3 (12.0)||11 (14.7)||0.793||0.203-3.108||0.740||6 (17.6)||8 (12.1)||1.554||0.492-4.909||0.453|
|NAT2*6A/*6A||2 (11.1)||2 (2.4)||5.000||0.655-38.152||0.121||2 (8.0)||2 (2.7)||3.174||0.423-23.812||0.261||1 (2.9)||3 (4.5)||0.636||0.064-6.360||0.700|
|NAT2*6A/*7B||3 (16.6)||2 (2.4)||8.000||1.230-52.023||0.029||1 (4.0)||4 (5.3)||0.74||0.079-6.945||0.792||2 (5.9)||3 (4.5)||1.313||0.209-8.257||0.772|
|NAT2*7B/*7B||1 (5.6)||0 (0)||-||-||-||0 (0)||1 (1.3)||-||-||-||0 (0)||1 (1.5)||-||-||-|
We have shown that a variant haplotype, NAT2*6A, of NAT2 is associated with susceptibility to anti-TB drug-induced hepatotoxicity, and a wild-type (major) haplotype, NAT2*4, is associated with non-susceptibility to hepatotoxicity. These findings suggest that NAT2 is one of the genetic factors responsible for predisposition to anti-TB drug-induced hepatotoxicity. However, since the number of TB patients in the present study was relatively small, it remains to be confirmed whether this association can be reproduced in a larger number of Japanese TB patients with and without hepatotoxicity as well as in other ethnic populations. Although previous reports have shown a positive association in Japanese TB patients between drug-induced hepatotoxicity and NAT2 variants with phenotypic activities of NAT2, such as rapid, intermediate, and slow acetylators[13,14,17], the present study is the first report demonstrating an association with NAT2-haplotype variation.
Three NAT2 haplotypes, NAT2*5B, NAT2*6A, and NAT2*7B, are believed to be associated with slow acetylators[24,29,30]. We did not detect NAT2*5B in our samples, probably because of its low frequency in the Japanese population as described in our previous study. Since NAT2 is the main enzyme involved in the metabolism of INH and NAT2*6A is functionally related to the low activity of N-acetylation in the INH metabolic pathway, TB patients possessing NAT2*6A may fail to metabolize toxic substances, such as hydrazine and acetylhydrazine, generated by INH metabolism in the liver, which therefore accumulate in the body, leading to drug-induced hepatotoxicity[21-23,31,32].
A variant diplotype, NAT2*6A/*7B, is associated with susceptibility to hepatotoxicity (P = 0.029). Although another NAT2-diplotype, NAT2*6A/*6A, showed a trend towards susceptibility to hepatotoxicity, the results were statistically not significant (P = 0.121). However, if a larger number of subjects were analyzed, NAT2*6A/*6A as well as NAT2*6A/*7B may demonstrate a significant association with hepatotoxicity. Both of these diplotypes are homozygous for variant haplotypes and indicate phenotypically slow acetylators. Therefore, it is likely that some of the slow acetylators who are variant homozygotes possessing the NAT2*6A haplotype have susceptibility to anti-TB drug-induced hepatotoxicity. In this context, the results of the present study with regard to NAT2-haplotypes/diplotypes are comparable to those of previous reports on the association between NAT2 phenotypic variation and hepatotoxicity[13-17,32]. Conversely, a wild-type homozygote, NAT2*4/*4, is associated with non-susceptibility and resistance to hepatotoxicity.
In conclusion, the haplotypes, NAT2*4 and NAT2*6A, are new biomarkers for predicting drug-induced hepatotoxicity, and may prove useful in achieving optimal treatment of individual TB patients.
We are grateful to TB patients and physicians for participating in this study.
Tuberculosis (TB) is a re-emerging infectious disease and has been declared a global health problem by the WHO. Adverse effect of anti-TB drugs including isoniazid (INH) has become a serious problem in the management of tuberculosis. Risk factors associated with the development of adverse effects include both clinical and genetic factors. Recently, genome-wide screening and candidate gene-based association studies have been launched to identify the possible susceptibility genes sensitive to anti-TB drugs.
Association studies with candidate gene-based approach in Asian and Caucasian patients have identified several possible susceptibility genes, e.g., N-acetyltransferase 2 (NAT2), cytochrome P450 2E1, glutathione S-transferase M1, glutathione S-transferase T1, and HLA-DQA1/-DQB1.
There are several reports on the association between NAT2 polymorphisms and adverse effects, especially hepatotoxicity, of anti-TB drugs from Japan, Taiwan, and India. However, NAT2 polymorphisms have been analyzed as phenotypic activities of NAT2, such as rapid, intermediate, and slow acetylators, but not as NAT2-haplotypes. The present study has shown that some phenotypically slow acetylators who are variant homozygotes possessing NAT2*6A haplotype have increased susceptibility to anti-TB drug-induced hepatotoxicity. This is the first report on the association with NAT2-haplotypes and hepatotoxicity in Japanese TB patients.
Our findings can be used for DNA-based diagnosis of TB patients before initiating treatment with anti-TB drugs, using NAT2*6A as a biomarker. Since patients possessing NAT2*6A haplotype have higher susceptibility to anti-TB-drug-induced hepatotoxicity, such individuals should be treated by reducing the dose of INH from 400 to 200 mg, in order to achieve optimal results.
NAT2 is the main enzyme in the INH metabolism, and is expressed in the liver. Single nucleotide polymorphism (SNP) is a DNA sequence variation which occurs when a single nucleotide in the genome differs in paired chromosomes of an individual. Haplotype is a combination of alleles at multiple linked loci that are transmitted together. A second interpretation is that a haplotype is a set of SNPs on a single chromatid that is statistically associated. Such information is very valuable in investigating the genetics behind common diseases. Restriction fragment length polymorphism (RFLP) is a laboratory technique designed to distinguish differing nucleotide sequences from two related contexts.
This study is well performed and the subject matter is very interesting.
|1.||World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2006. WHO/HTM/TB/2006.362. Genova, Switzerland: World Health Organization 2006; . [Cited in This Article: ]|
|2.||World Health Organization. Actions for life towards a world free of tuberculosis: the global plan to stop TB 2006-2015. WHO/HTM/STB/2006.35. Genova, Switzerland: World Health Organization 2006; . [Cited in This Article: ]|
|3.||Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis. 2002;185:1197-1202. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 169] [Cited by in F6Publishing: 44] [Article Influence: 8.9] [Reference Citation Analysis (0)]|
|4.||Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009-1021. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1584] [Cited by in F6Publishing: 628] [Article Influence: 88.0] [Reference Citation Analysis (0)]|
|5.||Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/STB/2006.361. World Health Organization, Genova, Switzerland. . [Cited in This Article: ]|
|6.||Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax. 1996;51:132-136. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 137] [Cited by in F6Publishing: 78] [Article Influence: 5.5] [Reference Citation Analysis (0)]|
|7.||Døssing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis. 1996;77:335-340. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 92] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis (0)]|
|8.||Devoto FM, González C, Iannantuono R, Serra HA, González CD, Sáenz C. Risk factors for hepatotoxicity induced by antituberculosis drugs. Acta Physiol Pharmacol Ther Latinoam. 1997;47:197-202. [PubMed] [Cited in This Article: ]|
|9.||Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother. 2004;38:1074-1079. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 64] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis (0)]|
|10.||Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, Tam CM, Leung CC, Lai CL. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology. 2000;31:201-206. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 163] [Cited by in F6Publishing: 107] [Article Influence: 7.8] [Reference Citation Analysis (0)]|
|11.||Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157:1871-1876. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 186] [Cited by in F6Publishing: 117] [Article Influence: 8.1] [Reference Citation Analysis (0)]|
|12.||Grönhagen-Riska C, Hellstrom PE, Fröseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis. 1978;118:461-466. [PubMed] [Cited in This Article: ]|
|13.||Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, Ogura T, Maeda K. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis. 2000;4:256-261. [PubMed] [Cited in This Article: ]|
|14.||Hiratsuka M, Kishikawa Y, Takekuma Y, Matsuura M, Narahara K, Inoue T, Hamdy SI, Endo N, Goto J, Mizugaki M. Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab Pharmacokinet. 2002;17:357-362. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis (0)]|
|15.||Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002;35:883-889. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 304] [Cited by in F6Publishing: 159] [Article Influence: 16.0] [Reference Citation Analysis (0)]|
|16.||Hussain Z, Kar P, Husain SA. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J Exp Biol. 2003;41:1226-1232. [PubMed] [Cited in This Article: ]|
|17.||Shimizu Y, Dobashi K, Mita Y, Endou K, Moriya S, Osano K, Koike Y, Higuchi S, Yabe S, Utsugi M. DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity. Tuberculosis (Edinb). 2006;86:374-381. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis (0)]|
|18.||Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, Chang FY, Lee SD. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology. 2003;37:924-930. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 289] [Cited by in F6Publishing: 159] [Article Influence: 16.1] [Reference Citation Analysis (0)]|
|19.||Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, Majumder PP. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol. 2001;16:1033-1037. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 120] [Cited by in F6Publishing: 63] [Article Influence: 6.0] [Reference Citation Analysis (0)]|
|20.||Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med. 2002;166:916-919. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 203] [Cited by in F6Publishing: 117] [Article Influence: 10.7] [Reference Citation Analysis (0)]|
|21.||Timbrell JA. Studies on the role of acetylhydrazine in isoniazid hepatotoxicity. Arch Toxicol Suppl. 1979;1-8. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis (0)]|
|22.||Noda A, Hsu KY, Noda H, Yamamoto Y, Kurozumi T. Is isoniazid-hepatotoxicity induced by the metabolite, hydrazine? J UOEH. 1983;5:183-190. [PubMed] [Cited in This Article: ]|
|23.||Lauterburg BH, Smith CV, Todd EL, Mitchell JR. Oxidation of hydrazine metabolites formed from isoniazid. Clin Pharmacol Ther. 1985;38:566-571. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis (0)]|
|24.||Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem. 1990;265:12757-12760. [PubMed] [Cited in This Article: ]|
|25.||Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11:272-276. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 733] [Cited by in F6Publishing: 167] [Article Influence: 24.4] [Reference Citation Analysis (0)]|
|26.||Available from: http: //www.louisville.edu/medschool/pharmacology/NAT2.html. [Cited in This Article: ]|
|27.||Machida H, Tsukamoto K, Wen CY, Narumi Y, Shikuwa S, Isomoto H, Takeshima F, Mizuta Y, Niikawa N, Murata I. Association of polymorphic alleles of CTLA4 with inflammatory bowel disease in the Japanese. World J Gastroenterol. 2005;11:4188-4193. [PubMed] [Cited in This Article: ]|
|28.||Machida H, Tsukamoto K, Wen CY, Shikuwa S, Isomoto H, Mizuta Y, Takeshima F, Murase K, Matsumoto N, Murata I. Crohn's disease in Japanese is associated with a SNP-haplotype of N-acetyltransferase 2 gene. World J Gastroenterol. 2005;11:4833-4837. [PubMed] [Cited in This Article: ]|
|29.||Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995;57:581-592. [PubMed] [Cited in This Article: ]|
|30.||Gross M, Kruisselbrink T, Anderson K, Lang N, McGovern P, Delongchamp R, Kadlubar F. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev. 1999;8:683-692. [PubMed] [Cited in This Article: ]|
|31.||Dickinson DS, Bailey WC, Hirschowitz BI, Soong SJ, Eidus L, Hodgkin MM. Risk factors for isoniazid (NIH)-induced liver dysfunction. J Clin Gastroenterol. 1981;3:271-279. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 56] [Cited by in F6Publishing: 37] [Article Influence: 1.4] [Reference Citation Analysis (0)]|
|32.||Yamamoto T, Suou T, Hirayama C. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology. 1986;6:295-298. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 46] [Cited by in F6Publishing: 30] [Article Influence: 1.3] [Reference Citation Analysis (0)]|